CHANGE THE CONTENT OF THE APO B WITH THE DEVELOPMENT OF EXPERIMENTAL HYPERCHOLESTEROLEMIA AND WAYS TO CORRECT IT

Azizova, Dilzoda; Sabirova, Rikhsi; Khalilova, R

dc.contributor.author	Azizova, Dilzoda
dc.contributor.author	Sabirova, Rikhsi
dc.contributor.author	Khalilova, R
dc.date.accessioned	2021-12-29T16:17:11Z
dc.date.available	2021-12-29T16:17:11Z
dc.date.issued	2019-05
dc.identifier.issn	2455-3301
dc.identifier.issn	WJPMR
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/1294
dc.description.abstract	The study examined the effect of Biomaysa on the content of apoprotein in and total cholesterol, lipoprotein cholesterol in the dynamics of experimental hypercholesterolemia. Apoprotein B. of combined administration Biomaysa and ultroksa installed significant difference in the reduction of total cholesterol levels in ApoB 2.2 and 1.5, indicating good cholesterol reducing the effectiveness of the combination of these drugs by activating LDL receptor capture.	en_US
dc.language.iso	en	en_US
dc.publisher	WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH	en_US
dc.subject	experimental hypercholesterolemia, blood, atherosclerosis, lipoproteins, cholesterol, apoprotein B.	en_US
dc.title	CHANGE THE CONTENT OF THE APO B WITH THE DEVELOPMENT OF EXPERIMENTAL HYPERCHOLESTEROLEMIA AND WAYS TO CORRECT IT	en_US
dc.type	Article	en_US